Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,231 across all filing types
Latest filing 2024-01-08 Major Shareholding Noti…
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
112年12月內部人持股異動(事後)
Major Shareholding Notification Classification · 95% confidence The document consists of detailed tabular data showing shareholdings of insiders, including directors and their related parties, with specific numbers of shares held, changes in holdings, and classifications of share types. The content focuses on insider shareholding disclosures rather than financial results, management changes, or other corporate events. This type of document aligns with the definition of a Major Shareholding Notification, which reports changes or status of significant share ownership levels by insiders or major shareholders. There is no indication that this is an announcement of a report publication, a financial report, or a regulatory certification. Therefore, the document is best classified as a Major Shareholding Notification (MRQ).
2024-01-08 Chinese
112年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings and pledges of shares by insiders, including directors, supervisors, and senior management of the company. It lists the number of shares held, pledged shares, and related percentages. The content is focused on insider shareholdings and their changes, which aligns with reporting insider transactions or holdings. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The document is not a report publication announcement or a certification. Given the focus on insider shareholdings and the nature of the data, the most appropriate classification is Director's Dealing (DIRS). The document length (5674 characters) supports it being a substantive report rather than a brief announcement.
2024-01-08 Chinese
本公司受邀參加J.P. Morgan舉辦之2024 Healthcare Conference
Investor Presentation Classification · 90% confidence The document is a short announcement (769 characters) about the company 1789 神隆 participating in the J.P. Morgan 2024 Healthcare Conference. It specifies the date, time, and location of the investor presentation and mentions that the company will discuss previously disclosed financial data and operational overview. There is no actual financial data or detailed report content included, only an announcement of the event and where to find more information. According to the 'MENU VS MEAL' rule, this is an announcement of an investor presentation, not the presentation itself. Therefore, the correct classification is Investor Presentation (IP).
2024-01-05 Chinese
112年12月法人說明會簡報 — 178920231207E001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'ScinoPharm Investor Conference 2023 12 07' and contains detailed company overview, business updates, financial performance including consolidated income statement, balance sheet, and cash flow statement for 3Q 2023. It also includes sales distribution by business, indication, and region, as well as a Q&A section. The content is comprehensive and includes actual financial data and analysis for a quarterly period. The length is substantial (over 14,000 characters), indicating it is not a brief announcement or a simple presentation. The presence of detailed financial statements and business updates aligns with the characteristics of an Interim / Quarterly Report rather than just an earnings release or investor presentation. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2023-12-07 Chinese
112年12月法人說明會簡報 — 178920231207M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation from ScinoPharm Taiwan, Ltd. dated December 7, 2023, containing extensive information about the company's business overview, product lines, market presence, financial performance including consolidated income statement, balance sheet, and cash flow statement for the first three quarters of 2023, as well as Q&A sections. It includes financial data and analysis for a period shorter than a full fiscal year (2023 Q3), with substantive financial tables and business outlook. The document is not a brief announcement or a certification but a comprehensive report with financial statements and business details. This matches the definition of an Interim / Quarterly Report (IR).
2023-12-07 Chinese
112年12月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's upcoming or recent investor presentation event (法人說明會 translates to 'investor presentation' or 'analyst meeting'). It includes the company code, name, date, time, location, and links to presentation materials in Chinese and English. The content focuses on a scheduled or held investor presentation discussing financial results and operational overview. The document length is short (756 characters) and it is clearly a presentation announcement or summary rather than a full financial report. Therefore, the appropriate classification is Investor Presentation (IP).
2023-12-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.